Clinical Trials of the Week: Phase III treatment studies for breast cancer

By Donna Loyle, communications manager, LIMR

 

As we close out October as Breast Cancer Awareness Month, we highlight the following clinical trials, which are randomized, phase III treatment studies:

  •  NRG-BR004 is comparing paclitaxel/trastuzumab/pertuzumab with either atezolizumab or placebo in first-line, HER2-positive metastatic breast cancer.
  • A011502 seeks to determine if simple aspirin can prevent breast cancer recurrence in patients with node-positive, HER2-negative, stage 2-3 cancer after chemotherapy, surgery and/or radiotherapy.

 

The principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. For more, click on the links for each trial above, or email cancertrials@mlhs.org.

Posted in Uncategorized | Leave a comment

21st Century Cures Act: Weekly Update & Tip Sheets

Sent on behalf of Don Klingen, MD & John Potts, DO

 

Colleagues,

 

We continue to prepare for the 21st Century Cures Act legislation that advocates for patients to have secure, ready access to their electronic medical records. This legislation goes into effect one week from today, on Monday, November 2.

 

We are committed to making sure our providers are prepared for this change, and will continue to provide weekly updates following the launch to make sure we are answering your questions and addressing your concerns. We are also educating our patients. This Wednesday, Oct. 28, an email will be sent to all Main Line Health MyChart users to notify them that they will soon have access to imaging, lab and radiology results and provider notes through their MyChart account. We will also share this information on our mainlinehealth.org website for patients.

 

As a result of our efforts to notify our patients of this change, please know that you and your staff may receive questions about these changes. Attached are:

  • A Q&A to assist you and your staff with answering questions from patients
  • A flyer notifying patients of this change, to be printed and displayed in your office Last week, we shared with you tip sheets about direct and respectful communication in Open Notes.

    This week, please see the attached tip sheet that outlines MyChart access for pediatric patients. Please consult this sheet for more information about the health information and access that adolescents and their proxies have to a MyChart account. We hope that you will find these to be helpful resources as we prepare to adopt this legislation next week. You can access all tip sheets and FAQ documents on the 21st Century Cures Act Wellspring page.  We hope these emails have been informative to you, but we understand you may have additional questions that we have not yet addressed. Please join us for the Medical Staff Town Hall this Wednesday, October 28 at 5:00 PM, where we will devote time to discussing the legislation and answering your questions. You will be able to ask questions during the chat, but you can also send questions ahead of time to Communications@MLHS.org.  At any point, should you have questions or concerns, please reach out to your chairs or VPMA.

Sincerely,

 

Don Klingen, MD

Senior Vice President & Chief Medical Information Officer

 

John Potts, DO

Assistant Chief Medical Information Officer

Posted in Uncategorized | Leave a comment

2020-2021 MLH Medical Staff Meetings

Mark your calendars!

 

Attendance at 50% (1) Hospital Staff meeting per Calendar Year is required for Active Staff members by the MLH Medical Staff Bylaws.

 

You may attend any ONE of the following meetings, at the hospital of your choice, whether that hospital is/is not your primary facility.

 

THERE ARE NO EXCUSED ABSENCES.

 

Spring 2021 Meetings

 

Tuesday, April 6, 2021                       6:00PM            Paoli Hospital

Thursday, May 6, 2021                       6:00PM            Riddle Hospital

Wednesday, May 12, 2021                 5:30PM            Bryn Mawr Hospital

Tuesday, June 8, 2021                       5:00PM            Lankenau Medical Center

 

The meetings will be held virtually due to the MLH meeting restrictions associated with the COVID-19 pandemic.  There will be no on-site in-person meeting.  The link and phone number to access the meetings will be emailed prior to each meeting.

 

Questions? Contact the Medical Staff Affairs Office at 484-337-8031

Posted in Uncategorized | Leave a comment

Clinical Trials of the Week: Treatment studies for patients with early-stage breast cancer

By Donna Loyle, communications manager, LIMR

 

October is National Breast Cancer Awareness Month, which makes this a great time to highlight our breast cancer clinical trials. Three of the 11 breast cancer trials for which we’re currently enrolling patients are for those with low-risk, early-stage disease. These are randomized phase III treatment studies:

  • Tailor RT, for patients with low-risk, node-positive breast cancer, is testing if patients must receive regional radiotherapy. Eligible participants must already have been treated with breast-conserving surgery or mastectomy and will receive endocrine therapy for five years.
  • BWEL is for patients diagnosed with early-stage breast cancer and interested in losing weight. Researchers seeks to determine if weight loss and exercise lower the risk of cancer recurrence.
  • NSABP B-51 is for patients with T1-3, N1 breast cancer and who have undergone at least eight weeks of standard chemotherapy. Researchers are comparing comprehensive radiotherapy (RT) to standard RT.

 

The principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. For more, click on the links for each trial above, or email cancertrials@mlhs.org.

Posted in Uncategorized | Leave a comment

COVID-19 Town Hall Medical Staff

Next week’s Medical Staff Town Hall on Wednesday, October 28 will be a brief COVID update followed by a presentation about the 21st Century Cures Act and its implementation at MLH. Please join us to learn more or submit questions. You can submit questions ahead of time by emailing Communications@MLHS.org.

Posted in Uncategorized | Leave a comment

21st Century Cures Act: Weekly Update & Tip Sheets

Colleagues,

 

As we announced last week, Main Line Health is preparing for the 21st Century Cures Act, legislation that goes into effect on Monday, November 2 at health systems across the country.

 

This act is the latest in a series of federal legislation that advocates for patients to have secure, ready access to their electronic medical records. This federal law applies to all providers and practices with an electronic medical record system, not just MLH’s instance of Epic. Independent providers should contact their EMR vendor to make sure they are compliant with the changes in the law.

 

One of the most significant changes that will occur as a result of this act is that provider notes will be automatically available to patients in their MyChart patient portal immediately following an appointment or discharge from the ED or hospital. While notes created prior to November 2 will not be released, patients do have the option to request them through the usual HIM request process.

 

This change is an important one and is a part of providing patients with the information they need to manage their care and take charge of their health. However, this will necessitate some changes to the manner and language in which these provider notes are written, as these are now not only intended for providers and other medical professionals—but for patients, as well.

 

You can find the tip sheets and FAQ documents on Wellspring. The first tip sheet is intended to help you introduce open notes to patients and set expectations for the information they can expect to find in these notes. The second is a guide to using direct, clear and respectful language regarding a variety of health issues. We hope that you will use these as a resource.

 

As we approach November 2, you will continue to hear more about how Main Line Health is preparing providers, patients and employees for the new access offered by the 21st Century Cures Act. Emails will be sent weekly to providers, with a new set of tip sheets each week to help you navigate the changes brought forth by this legislation.

 

At any point, should you have questions or concerns, please reach out to your chairs or VPMA.

 

Sincerely,

 

Don Klingen, MD

Senior Vice President & Chief Medical Information Officer

 

John Potts, DO

Assistant Chief Medical Information Officer

 

Posted in Uncategorized | Leave a comment

Clinical Trial of the Week: Dosage study to treat patients with symptomatic PAH

By Donna Loyle, communications manager, LIMR

 

Researchers, including those at Main Line Health, are conducting a phase III, multicenter, double-blind, randomized study to compare Opsumit® (macitentan) 75 mg vs. 10 mg in patients with symptomatic pulmonary arterial hypertension (PAH). It is followed by an open-label treatment period with macitentan 75 mg.

 

Participants who have never taken an endothelin receptor antagonist first receive 10 mg of macitentan orally daily for 4 weeks before being randomized into a study group. Those who previously have taken such medications are directly randomized into a study arm.

 

Patients in the two study arms receive the following daily:

  • Arm 1 receives macitentan 10 mg orally and placebo for 4 weeks, and then 75 mg of macitentan thereafter until the end of the double-blind treatment period. During a treatment extension period, participants receive 37.5 mg of mactientan and placebo for 4 weeks.
  • Arm 2 receives maceitentan 37.5 mg and a placebo for 4 weeks, then 75 mg and a placebo until the end of the double-blind treatment period. During a treatment extension period, Arm 2 participants receive 75 mg of mactientan and placebo for 4 weeks.

 

Both groups then receive mactitentan (75 mg) alone daily for 2 years.

 

Note: There are body weight restrictions to this trial; the trial coordinator can give further details. Patients must be able to perform a 6-minute walking test at time of screening.

 

Steven Domsky, MD, is the MLH principal investigator for the UNISUS trial that is approved for Lankenau Medical Center. For more, visit https://www.mainlinehealth.org/research/clinical-trials/unisus

Posted in Uncategorized | Leave a comment

Melanoma virtual seminar

Ned Carp, MD, of MLH Department of Surgery, and Marie Webster, PhD, assistant professor at Lankenau Institute for Medical Research, will give a one-hour Dynamic Duo virtual seminar on melanoma. Tuesday, Oct. 20, noon to 1 p.m.

 

Attendees of this Zoom-based webinar will learn about:

  • mechanisms of stress response and therapy resistance in melanoma;
  • challenges to current and potential therapies in metastatic disease;
  • different types of skin cancer and screening strategies; and
  • treatment modalities for malignant melanoma.

 

Continuing medical education credits for physicians are available for this seminar.

 

Please click this URL to join: https://mlhs.zoom.us/j/96339265405?pwd=NXFRNjhNS2huYVhyVlEwbitCTE9hQT09

Passcode: 407530

 

Or join by phone: US: +1 929 205 6099

Webinar ID: 963 3926 5405

For more information, please see the attached flyer.

Posted in Uncategorized | Leave a comment

Heart Walk only three weeks away

The Heart Walk is only three weeks away. A reminder that the Heart Walk will take place during the week of November 2nd.

To build our community, we need your help. Please make time today to join our Heart Walk team (it’s free and easy to register!).  To join our team, CLICK HERE and follow the instructions below:

  1. Click “Create a Team” or “Join a Team”
  2. Remember to choose the correct facility
  3. Create your profile
  4. Follow the prompts!

 

If you register as a walker online and make a $25 donation to a MLH team by October 23rd, you will receive a MLH t-shirt.

 

Information about t-shirt distribution and pick-up location(s) will be communicated to team captains and registered walks the week of October 26.

 

If you have questions, please contact Caitlin Petrakis at petrakisc@mlhs.org .

Posted in Uncategorized | Leave a comment

2020 Medical Licensure Renewal Requirements

  • 2 hours of continuing education in Pain Management, Identification of Addiction, or Practices of Prescribing or Dispensing of Opioids (Category 1 or 2 Credit)
  • 2 Hours of continuing education in Child Abuse Recognition and Reporting
    • DO licenses expire October 31, 2020
    • MD & DPM licenses expire December 31, 2020

 

OPIOID EDUCATION

 

MLH – The Nuts and Bolts of Responsible Pain Management
Available on MediaSite (Category 2 Credit); link is below; sign in using your MLH Network username and password; click on CME Folder

 

https://mediasite.mlhs.org/Mediasite/Login?ReturnUrl=%2fMediasite%2fPlay%2f63496e107e5348af835523a42a60093b1d

 

Pennsylvania Medical Society online webinars

The PA Medical Society has several activities available online for physicians to meet the requirements for opioid education: (for PMS members only)

 

https://www.pamedsoc.org/education-cme/CME-Tracker/TakeCME/addressing-pas-opioid-crisis

 

Child Abuse Recognition and Reporting

  • On-line CME Course must be taken prior to submitting licensure renewal application
  • License will not be renewed if renewal application is received prior to verification of course completion
  • The State approved course provider will electronically notify the State Board of Medicine you have taken the course (takes approximately 7 days for notification to reach the Board)

 

    • State Approved Child Abuse Recognition and Reporting Courses

 


http://keepkidssafe.pa.gov/resources/training/index.htm

Posted in Uncategorized | Leave a comment